Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
114,603
Sort by:
UK Occupational Health Market Development Report
US$ 1,135.00
The UK occupational health market research report by MBD analyses the market size and the trends in this emerging market. Other major issues covered ... and health screening. The report analyses the industry structure development and together with 6 company profiles. This updated report also provides five year ...
March 2013
87 pages
PET Scanner Market in India 2013
US$ 950.00
... a snapshot of the PET scanner market. It begins with an overview of the major macro economic indicators of India which highlights the present economic ... includes competitive benchmarking of the top players operating in the PET scanner market in India. The report also provides brief profiles of the major ...
March 2013
41 pages
Ear Care in Australia
US$ 990.00
... subsequent incidence of swimmer’s ear represent a key driver of demand for ear care products in Australia. Ear care grew by 4% to reach sales of A$13 million in 2012. Blocked ears are also a symptom ... review period has also helped increase demand for ear care products. Euromonitor International's Ear Care in Australia report offers a comprehensive guide to the size and ...
March 2013
22 pages
Ear Care in Croatia
US$ 990.00
... by the economic downturn which continued in Croatia during 2012. This can partly be attributed to the fact that ear care is still a niche category, and is growing from a low base. Euromonitor International's Ear Care in Croatia report offers a comprehensive guide ...
March 2013
17 pages
UAE IVF Treatment Market Analysis
US$ 600.00
... be prevented. “UAE IVF Treatment Market Analysis” research report gives detailed information on following aspects related to booming IVF treatment market in UAE: Current Market Scenario IVF Treatment Market Potential Treatment cycle & Birth Rate Fertility Treatment Loan ...
March 2013
68 pages
Neuroprosthetics Market Analysis By Type (Motor Prosthetics, Auditory Prosthetics/Cochlear Implants, Cognitive Prosthetics, Visual Prosthetics/Retinal Implants), By Technology (DBS,VNS, SCS, SNS), By Application (Motor Neuron Disorders, Parkinson’s Disease, Epilepsy, Physiological Disorders, Auditory, Ophthalmic, Cardiac, Kidney, Cognitive, Alzheimer’s Disease, Severe Depression), And Segment Forecasts, To 2024
US$ 5,950.00
... technologically advanced implants is expected to drive the demand for neuroprosthetics market in the coming years. In addition, the associated high ... this segment’s growth. In 2015, North America dominated the overall neuroprosthetics market at over 43.0% owing to the large presence of neural implants ...
March 2013
91 pages
Smart Syringes Market Analysis by Therapeutic Category (Auto-Disable Syringes, Active Safety Syringes, Passive Safety syringes), By Application (Drug delivery, Vaccination, Blood Specimen Collection), By End-use (Hospitals and HMOs, Diabetic Patients, Family Practices (Physicians), Psychiatrists) And Segment Forecasts To 2024
US$ 5,950.00
... are expected to adopt the usage of smart syringes,which would significantly boost the smart syringes market over the forecast period. Further key findings ... the study suggest: In 2015, the auto-disable syringes segment dominated the smart syringes market with revenue of over USD 3.0 billion. The established ...
March 2013
92 pages
Weight Management Trends in the U.S., 2nd Edition
US$ 3,995.00
... States Obesity has reached crisis levels in the United States. Almost 70% of adults and almost 32% of school-age children and adolescents are either ... consumers use is changing. Now in its 2nd edition, Weight Management Trends in the U.S. identifies issues and trends affecting the marketplace and evaluates ...
February 2013
306 pages
China Hospital Industry Development and Investment Report, 2012-2015
US$ 2,300.00
... , and tumour hospitals as well as their development outlook; development prediction of China hospital industry: status quo of China medical security, boosting urbanization ... major privately-owned specialized hospitals in China, six listed companies that have accessed into the hospital industry, and two foreign ...
February 2013
120 pages
Digital Doctors: Marketing to Online Networks (2nd Edition)
US$ 595.00
... on physician communities – Digital Doctors: Marketing to Online Networks (2nd Edition) – is your definitive guide to the leading online physician networks in both developed and emerging markets: What are ... , Marketing Communications/Channels, Merck Sven Awege, pharma digital consultant (clients have included Eli Lilly and Doctors.net.uk) Tim Ringrose, CEO of Doctors.net ...
February 2013
52 pages
Healthcare Sector in India: Strategic Review (Budget 2013-14)
US$ 100.00
... at a much rapid pace than it was anticipated before and is expected to become a $238.76 billion industry by 2020. A number of major players in the healthcare sector are actively participating in the growth through expansion plans and putting in huge investments in the sector. According to the Investment ...
February 2013
8 pages
2013 Healthcare Benchmarks: Improving Medication Adherence
US$ 127.00
... and much more. Download the executive summary of 2013 Healthcare Benchmarks: Improving Medication Adherence. Medication management has long been a key to-do on the ... health plan members about proper use of prescribed medications is moving upstream to the medical home, community clinics, and even in the home ...
February 2013
56 pages
Guide to Population Health Management
US$ 249.00
... management — from keeping the healthy 'healthy' to coordinating care for complex patients and those with advanced illness — supports the widely ... adopters of a PHM approach. Download the executive summary of the Guide to Population Health Management. It also offers a primer in PHM, an advanced case study ...
February 2013
130 pages
Global Coronary Stent Market Report – 2013 Edition
US$ 800.00
... due to intensity and rate of increase of the disease. The coronary stents market has witnessed growth as well as decline phases in its journey. ... Japan and Europe/Rest of the world. The competition in the global coronary stent market is intense with few large players viz. Abbott Laboratories, Medtronic ...
February 2013
58 pages
Cell-Based Assays: World Market Prospects 2013-2023
US$ 2,635.00
... drugs) and biosimilars Miniaturisation and automation, including microfluidics Multiplexing - making assays more efficient High content screening (HCS) Outsourcing (off-shoring) ... , helping you stay ahead. Seven main ways Cell-Based Assays: World Market Prospects 2013-2023 helps In particular, then, our ...
February 2013
132 pages
Hoya Lens Hong Kong Ltd in Eyewear (Hong Kong, China)
US$ 150.00
Hoya Lens Hong Kong’s strategic direction is to focus on innovative technology and new product development, in order to address changing consumer lifestyles and interests. Accordingly, the company is making ongoing efforts in combining state-of- art technology with its extensive product knowledge, to offer a ...
February 2013
2 pages
Safilo Far East in Eyewear (Hong Kong, China)
US$ 150.00
Safilo Far East’s strategic focus is to become the leading player in eyewear via a wide product portfolio, which can appealing to a wide range of ... shares and distribution data. Why buy this report? Get a detailed picture of the Eyewear market; Pinpoint growth sectors and identify factors driving change; ...
February 2013
2 pages
Smartraoptics Co Ltd in Eyewear (Hong Kong, China)
US$ 150.00
SmarTraOptics strategically aims to expand outside Hong Kong and mainland China, with an emphasis on providing quality products and services. The company is ... distribution data. Why buy this report? Get a detailed picture of the Eyewear market; Pinpoint growth sectors and identify factors driving change; ...
February 2013
28 pages
HIV - KOL Insight and Consensus Outlook Modules
US$ 7,495.00
... FirstWord research is provided in two comprehensive modules: The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with ... Protease inhibitors CCR5 inhibitor Expert Opinion for Real World Insights The data and analysis in the report is enriched through the ...
February 2013
183 pages
SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
US$ 140.00
... FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought down SymBio pharma (4582 ... , please read our report released on 22nd February 2013 on SymBio titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!”
February 2013
4 pages
Bristol-Myers Squibb Co in Consumer Health (World)
US$ 520.00
... BMS will pursue these remains to be seen. Euromonitor International’s Bristol-Myers Squibb Co in Consumer Health (World) Company Profile offers detailed strategic ... data. Why buy this report?: Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...
February 2013
32 pages
Bristol-Myers Squibb Co in Consumer Health (Global)
US$ 572.00
Bristol-Myers Squibb Co, a US-based producer of pharmaceutical and consumer health products, is making increasingly definite steps away from consumer health in order to re-position itself as a bio-pharma ... International’s Bristol-Myers Squibb Co in Consumer Health (Global) Company Profile offers detailed strategic analysis of the company’s business, examining its performance in the Consumer Health industry ...
February 2013
32 pages
The Long Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living
US$ 3,196.00
... . These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report ... the Marketplace Competitors and Competitive Analysis Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are ...
February 2013
DR REDDY’S LAB - Growth to Slow Down on Higher Base, Margins to Remain Under Pressure
US$ 140.00
Dr Reddy’s Q3FY13 result was below our estimates as ... XL, ramp up of Fondaparinux (hospital segment) and Amoxil. We expect Dr. Reddy may participate in Vidaza opportunity which is due any time as an API ... US and Russia. We reiterate our market perform rating on Dr Reddy’s and retain out target price of Rs.1929.
February 2013
7 pages
INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!
US$ 140.00
... both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI). Despite limited clinical data in hand, PC and in vitro ... read our report released on 13th February 2013 on INFI titled “IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!”
February 2013
8 pages
Ear Care in Mexico
US$ 990.00
Ear care products to relieve pain are the most commonly used, followed by wax removal products. Euromonitor International's Ear Care in Mexico report offers a comprehensive guide ... data. Why buy this report? Get a detailed picture of the Ear Care market; Pinpoint growth sectors and identify factors driving change ...
February 2013
25 pages
GlaxoSmithKline México SA de CV in Consumer Health (Mexico)
US$ 150.00
GlaxoSmithKline México is one of the leading international pharmaceutical companies operating in the country, with a strategy of selling strong brands mostly to middle- and high-income consumers. As most international companies, GlaxoSmithKline has been operating in Mexico for decades, and manages very ...
February 2013
3 pages
Pfizer SA de CV in Consumer Health (Mexico)
US$ 150.00
... with OTC products taking second place. The recent acquisition of Wyeth by Pfizer Inc offered the company a better position within consumer health overnight: for example, Wyeth offers a comprehensive line of nutrition products, which Pfizer lacks. Both companies have been operating in the country for decades ...
February 2013
2 pages
Medicated Skin Care in the United Arab Emirates
US$ 990.00
... body) treatments, antipruritics, cold sore treatments and... Euromonitor International's Medicated Skin Care in United Arab Emirates report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
February 2013
26 pages
Therapeutic Class Report Overview - Hemophilia
US$ 2,000.00
Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used ...
February 2013
47 pages
Global and China Hemodialysis Industry Report, 2012-2013
US$ 2,200.00
... Science and Technology, etc. Given the huge potential in Chinese hemodialysis market, several listed companies have tapped into the field, ... landscape, import & export and development prediction of Chinese hemodialysis industry; Global and China hemodialysis equipment market segments and competition pattern ...
January 2013
91 pages
Brazilian Market for Wound and Tissue Management
US$ 6,995.00
... 2012, the total Brazilian market for wound and tissue management was valued at nearly $632 million. The Brazilian wound and tissue ... growth. Scope: This report pertains to a forecast period of 10 years (2008 – 2018) for Brazil. Report Contents: Competitor Analysis Identified Strategic Opportunities ...
January 2013
262 pages
European Wound and Tissue Management Markets
US$ 10,995.00
... wounds including surgical incisions, burns, and ulcers. The European wound and tissue management market is expected to be driven by an aging population and rising ... closure segments of the market. Technological developments such as negative pressure wound therapy and skin substitutes are also driving the market ...
January 2013
458 pages
Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)
US$ 800.00
... filled syringes a fast-growing alternative to vials for many parenteral drugs such as vaccines, anticoagulants and therapeutic proteins. The report titled “Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)” provides an in-depth analysis of the global prefilled syringes market with major focus on biggest healthcare markets of U.S and Europe. It also ...
January 2013
78 pages
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
US$ 495.00
... Pharma do to maximise the credibility and visibility of its products? Overview The Path to Product Inclusion in Clinical Guidelines: Strategies for Success If you ... defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical
January 2013
49 pages
Cellular Therapy and Cord Blood 2013 Market Report
US$ 2,119.00
... is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences. In this ... . Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. Our coverage provides hard numbers ...
January 2013
172 pages
New Horizons in Healthcare Case Management: Benchmarks, Metrics and Models
US$ 299.00
... more than 90 figures and tables and answers more than 50 questions on patient-centered case management. Download the executive summary and complete table of contents for New Horizons in Healthcare Case Management: Benchmarks, Metrics and Models. Market research by the Healthcare ...
January 2013
200 pages
Personalized Medicine Market Opportunities
US$ 229.00
... and scientists are looking at options for curing AIDS as well with personalized medicines. Often described as the right treatment for the right ... technology platforms as well as the technological requirements for the personalized medicines market. Challenges facing the industry as well as a look at the key ...
January 2013
178 pages
CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion
US$ 140.00
With our conservative view on Revlimid – opportunity in EU (no approval in NDMM and Maintenance setting), reimbursement in China, and patent challenges; we expect net product sales’ CAGR (2013-17) of 17% (vs. CELG’s guidance: 19%) including risk adjusted late stage pipeline. We are positive on upcoming ...
January 2013
6 pages
ROCHE, Confidence building up on next gen. Rituxan (GA101)
US$ 90.00
Roche seems to be on track of delivering sustainable growth as it announced ... forward. With Perjeta and T-DM1 as well shaping up well, Roche is on a strong ground to sustain its revenues from Herceptin ... expected to reach the market in 2016, but by then, Roche would have GA101 on the market which would fend off ...
January 2013
3 pages
DISHMAN, Worry on Cash Flow Continues
US$ 140.00
... visibility of free cash flow generation, we continue to remain concerned about the fate of highly levered (operating and financial) business model of Dishman. The fact ... land clearly signifies that company is not generating sufficient free cash flow to service its debt. As the proposed sale of SEZ land has ...
January 2013
6 pages
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
US$ 2,000.00
... (CELG) M&A in Kinase Inhibitors in the last 5 years Related Milestones/catalysts in 2013-14 Combination Studies – PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological ...
January 2013
62 pages
GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory
US$ 140.00
nitial sales of newly added HIV products – Complera/ Eviplera (L, truvada + rilpivirine), Stribild (L in US, ... products contributed to the impressive 4Q12/FY13 results of Gilead. Positive data of Sofosbuvir (PMI, PhIII) in ... Through life cycle management of products for HIV, late stage HCV drugs and focus on ...
January 2013
8 pages
